Skip to main content
NRXP
NASDAQ Life Sciences

FDA Greenlights NRXP's NRX-101 Phase 2/3 Trial for Suicidal Depression

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.05
Mkt Cap
$100.856M
52W Low
$1.62
52W High
$3.84
52W Position info
88% above low
Off High info
21% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

NRXP sits 88% above its 52-week low of $1.62.

Summary

NRx Pharmaceuticals has received FDA clearance to proceed with a Phase 2/3 clinical trial for NRX-101, its drug candidate for depression and suicidality, in combination with robotic-enabled transcranial magnetic stimulation. This is a significant regulatory milestone for the clinical-stage biopharmaceutical company. This positive development follows the company's recent 10-K filing, which included a 'going concern' warning and highlighted substantial share dilution from a prior at-the-market equity offering. The company anticipates that this newly approved trial will be supported through non-dilutive sources, which is a crucial factor given its recent financial challenges. Advancing a key asset like NRX-101, which holds Breakthrough Therapy Designation, into a pivotal trial with potentially non-dilutive funding, is a material positive catalyst for the stock. Investors will now watch for updates on trial initiation, patient enrollment, and the securing of the anticipated non-dilutive funding.

At the time of this announcement, NRXP was trading at $3.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.9M. The 52-week trading range was $1.62 to $3.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

NRXP - Latest Insights

NRXP
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $2.17 info
Change: -$0.8097 (-27%) info
Market Cap: $95.585M info
NRXP
Oct 15, 2026, 8:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $2.17 info
Change: -$0.3799 (-15%) info
Market Cap: $95.585M info
NRXP
Oct 05, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.86
Real-time Price: $2.17 info
Change: -$0.6899 (-24%) info
Market Cap: $95.585M info
NRXP
Sep 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.98
Real-time Price: $2.17 info
Change: -$0.8144 (-27%) info
Market Cap: $95.585M info
NRXP
Sep 15, 2026, 9:17 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.35
Real-time Price: $2.17 info
Change: -$1.18 (-35%) info
Market Cap: $95.585M info